ArticleBMC cancer2025
CTHRC1-driven breast cancer progression: insights from palmitoylation networks and spatial heterogeneity.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study systematically screened palmitoylation-related key biomarkers in breast cancer and constructed a high-precision diagnostic model combining multi-omics data and machine learning algorithms. Following batch effect correction across datasets via the ComBat algorithm, 1,782 differentially expressed genes (DEGs) were identified and showed significant enrichment during the extracellular matrix remodeling process and in the PI3K-Akt signaling pathway, highlighting their potential roles in the regulation of cellular microenvironment and the activation of signaling network. A total of 5 core genes (HBB, BGN, CTHRC1, FABP4, CD34) were screened using three machine learning methods. Further analysis of gene contribution revealed that CTHRC1 served as the key gene to affect the prediction of the model. SHAP interpretability analysis highlighted CTHRC1 as a primary contributor to prediction models. Spatial transcriptomic mapping revealed that focal high expression of CTHRC1 in tumor tissues was correlated with enhanced microenvironmental heterogeneity. Functional assays demonstrated that CTHRC1 knockdown can significantly attenuate cell proliferation and clonogenic potential of breast cancer. These findings collectively elucidate that palmitoylated CTHRC1 drives breast cancer progression by enhancing tumor cell proliferation and microenvironment heterogeneity. Clinically, CTHRC1 has shown potential as a diagnostic biomarker and therapeutic target—laying the foundation for the development of liquid biopsies and therapeutic targets based on CTHRC1 to improve the precision management of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.